Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 20

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 20
---
 and expects the proceeds of this offering to contribute materially to the satisfaction of the Stockholders’ Equity Requirement. Warrant Issuances On December 23, 2024, the Company issued warrants to purchase an aggregate of 84,059 shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq on December 20, 2024, to certain institutional investors as a condition to the exercise of Preferred Warrants held thereby. On January 6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares of Common Stock, with an exercise price of $5.82 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025, to an institutional investor as a condition to the exercise of Preferred Warrants held thereby. Such number of shares and the exercise prices give effect to the Reverse Stock Split (as defined below). Reverse Stock Split At 12:01 a.m. Eastern time on January 8, 2025, we effected a reverse stock split (the “Reverse Stock Split”) pursuant to which each 100 shares of our Common Stock outstanding immediately prior thereto was converted into 1 share of our Common Stock outstanding immediately thereafter. Cash Balance On January 7, 2025, the Company reported that, as a result of the receipt of proceeds from the warrant issuances described above, as well as issuances of shares of Common Stock pursuant to the New Keystone Purchase Agreement from December 6, 2024 through January 6, 2025, the Company had a cash balance of approximately $5.539 million as of January 7, 2025. Summary Risk Factors Investing in our securities involves risks. If any of these risks actually occur, our business, financial condition and results of operations would likely be materially adversely affected. You should carefully consider all the information contained in this prospectus before making a decision to invest in our securities. In particular, you should consider the risk factors described under “ Risk Factors” beginning on page 9. Some of the principal risk factors are summarized below:

| ● | the shares of Common Stock                                                                                                           
 being offered in this prospectus represent a substantial percentage of the outstanding shares of Common Stock, and the sales of such 
 shares, or the perception that these sales could occur, could cause the market price of the Common Stock to decline significantly.   |

| ● | sales of a substantial